SYGNIS AG announces Genetrix S.L. has taken over all shares from Genetrix Life Sciences AB to become new majority shareholder

SYGNIS AG / Key word(s): Miscellaneous

2015-06-03 / 13:00


Press Release

SYGNIS AG announces Genetrix S.L. has taken over all shares from Genetrix Life Sciences AB to become new majority shareholder

Genetrix S.L., as the parent company, now acts as a direct shareholder

No substantial change in SYGNIS shareholder structure

Madrid, Spain and Heidelberg, Germany, June 3rd, 2015 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that Genetrix S.L. has informed the Company that it has transferred all common shares currently held by Genetrix Life Sciences AB to Genetrix S.L.

Due to internal corporate changes, Genetrix S.L. will assume the shareholding in SYGNIS AG from its fully owned subsidiary Genetrix Life Sciences AB. In light of the holding transfer, Genetrix S.L. will become the majority shareholder in SYGNIS. Genetrix S.L. has informed the Company that it has filed the transfer of all common shares currently held by Genetrix Life Sciences AB to Genetrix S.L. with the BaFin. This transfer does not represent any change to SYGNIS’ ownership structure.

For further information please contact:

SYGNIS AG
Pilar de la Huerta
CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com
 
MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 30
Email: raimund.gabriel@mc-services.eu

 

About SYGNIS AG: www.sygnis.com

Following the merger with X-Pol Biotech in 2012, SYGNIS specializes on the development and commercialization of products for DNA amplification and sequencing. SYGNIS AG, listed at the German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), has a commercial product for whole genome DNA amplification, SensiPhi(R), licensed to an industry leading partner and two own product lines on the market: TruePrime(TM) based on its proprietary TruePrime(TM) technology for whole genome amplification and SunScript(TM) Reverse Transcriptase to convert genetic information from RNA molecules back to DNA. Both product lines are addressing key challenges in the fast growing fields of molecular biology and next generation sequencing applications.

### Disclaimer

This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.###


2015-06-03 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de



364895  2015-06-03